AIM:To observe the preliminary efficacy of conbercept injected intravitreally for the treatment of wet age-related macular degeneration(wAMD).

METHODS:Seventeen wAMD patients(18 eyes)were selected to receive conbercept injection. All patients were given a single conbercept injection every month, 3 times. Before and after 1, 2, 3mo of the injection, the best corrected visual acuity(BCVA), intraocular pressure(IOP, measured by Non-contact tonometer), fundus photography, fundus fluorescein angiography(FFA), indocyanine green angiography(ICG), optical coherence tomography(OCT)examination and the complications incidence were compared.

RESULTS:Three months after conbercept injection, the BCVA improved in 15 eyes(83%), stable in 3 eyes(17%). Before treatment, the average central macular thickness was 421.72±54.43μm, at 1 and 2 and 3mo after treatment, the average central macular thickness was 337.89±25.88μm, 293.56±26.87μm, 266.89±19.10μm respectively. There were significant differences compared with before and after injection(P<0.05). In the final follow up, FFA and ICG showed that the leakage in macular area disappeared in 15 eyes(83%), still existed in 3 eyes(17%), in those 3 eyes the injection was given for one or two times till the leakage disappeared. Elevated intraocular pressure occurred in 2 cases(26mmHg, 23mmHg), after 1d down to normal. Another patient showed postoperative envy, given left ofloxacin eye drops after 2d,then back to normal. There was no serious ocular adverse reactions.

CONCLUSION:Intravitreal injection conbercept for wAMD can significantly improve the visual function, reduce the macular edema and the leakage with higher safety and less complications. However the prolonged efficacy needs further observation.